Welcome to the e-CCO Library!

DOP01: A multi-centre study to explore the prevalence of Inflammatory Bowel Disease indicators in patients with moderate- to- severe psoriasis: Baseline results from the EPIC study
Year: 2022
Source: ECCO'22
Authors: Hayee, B.(1);Ghosh, S.(2);Carter, B.(3);Bartlett, S.(4);Powles, E.(4);Millward, R.(4);Watcham, S.(4);Blanthorn-Hazell, S.(4);Crooks, J.(4);Hansell, C.(4);Millar, J.(5);Williams, C.(5);Migas, S.(5);Hajne, J.(5);Warren, R.(6);
Created: Friday, 11 February 2022, 3:52 PM
Last Modified: Friday, 4 March 2022, 1:45 PM by Dietrich Diz Angerer-GTN
DOP01: Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper
Year: 2024
Source: ECCO'24 Stockholm
Authors: Rosini, Francesca
Created: Tuesday, 30 April 2024, 5:03 PM
DOP01: Efficacy and safety of the IL-6 trans-signalling inhibitor olamkicept: a phase 2 randomized, placebo-controlled trial in moderately to severely active Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Chen, B.(1);Zhang, S.(1);Wang, B.(2);Chen, H.(3);Li, Y.(4);Cao, Q.(5);Zhong, J.(6);Xie, M.(7);Ran, Z.(8);Tang, T.(9);Yang, M.(10);Guo, T.(10);Xu, B.(10);Cai, Z.(10);Schreiber, S.(11);Chen, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
DOP01: Exclusive enteral nutrition for treatment of Adult Crohn's Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Liz Purcell
Created: Tuesday, 23 June 2020, 5:40 PM
DOP01: Exclusive enteral nutrition for treatment of Adult Crohn's Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Liz Purcell
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP01: Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT): possible new target and biomarker in inflammatory bowel diseases
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Colombo*1, C. Travelli1, C. Porta1, G. Stocco2, F. Malavasi3, A. A. Genazzani1

Created: Friday, 22 February 2019, 9:41 AM
DOP01: The effect of vedolizumab on CD8 T cell repertoire homogeneity and blood-gut trafficking in patients with inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: James Lord
Created: Friday, 14 July 2023, 2:22 PM
DOP01: The effect of vedolizumab on CD8 T cell repertoire homogeneity and blood-gut trafficking in patients with inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Williams, K.(1);Shows, D.(2);Kongala, R.(2);Clarke, A.(3);Lord, J.(2)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP02 The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V. Svolos1, K. Gkikas1, V. Rizou1, E. Christina1, P. Kapranos1, J. Kleingunnewiek1, J.P. Seenan2, J. Macdonald2, D.R. Gaya3, R. Hansen4, R.K. Russell4, K. Gerasimidis1

Created: Thursday, 30 January 2020, 10:12 AM
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Yarur A.*1, Bruss A.1, Jain A.2, Kondragunta2 V.2, Hester K.2, Luna T.2, Agrawal D.1, Patel A.1, Fox C.1, Werner S.1, Naik S.2, Stein D.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumab
Year: 2017
Source: ECCO'17 Barcelona
Authors: Yarur A.
Patient reported outcomes, Therapeutic drug monotoring, Pharmacokinetics, Treat to tatrget, Vedolizumab
Files: 1
DOP020: Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohns disease: pooled results from the ASTIC trial
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. Lindsay*1, M. Allez2, M. Clark3, M. Labopin4, E. Ricart5, G. Rogler6, M. Rovira7, J. Satsangi8, D. Farge9, C. Hawkey3

Created: Friday, 22 February 2019, 9:49 AM
DOP020: Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn’s disease: pooled results from the ASTIC trial
Year: 2016
Source: ECCO'16 DOP
Authors: Lindsay J.
stem cell transplantation/therapy, clinical trials, Crohn's Disease
Files: 1
DOP020: Thiopurine monotherapy still has a place in the treatment of patients with mild-to-moderate Crohn’s disease in the biological era
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Verstockt1,2*, L. Boets1, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP020:Thiopurine monotherapy still has a place in the treatment of patients with Mild-to-Moderate Crohn’s Disease in the biological era
Year: 2018
Source: ECCO'18 Vienna
Authors: Verstockt Bram
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn’s disease: 10-year follow-up data from the Swiss IBD cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Cernoch1, N. Fournier2, M. Scharl1, J. Zeitz3, B. Morell1, T. Greuter1, P. Schreiner1, B. Misselwitz1, E. Safroneeva4, A. Schoepfer5, S.R. Vavricka6, G. Rogler1, L. Biedermann on behalf of the Swiss IBD Cohort Study Group7*

Created: Thursday, 21 February 2019, 9:14 AM
DOP021: Long term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohn’s disease: ten years of Milan experience without CD34+ cell selection.
Year: 2016
Source: ECCO'16 DOP
Authors: Cassinotti A.
stem cell transplantation/therapy, clinical trials, Crohn's Disease
Files: 1
DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vermeire S.*1, Loftus E.V.2, Colombel J.-F.3, Feagan B.4, Sandborn W.5, Sands B.6, Danese S.7, D'Haens G.8, Kaser A.9, Panaccione R.10, Rubin D.11, Shafran I.12, O'Byrne S.13, Geransar P.13, Previtali A.14, Khalid J.M.15, Kaviya A.16

Created: Wednesday, 20 February 2019, 10:36 AM